Mylan, Genentech Strike Deal For Herceptin Biosimilar
Mylan NV on Monday said it has agreed to drop its challenge of two Genentech Inc. patents related to the cancer biologic Herceptin as part of a deal that will get...To view the full article, register now.
Already a subscriber? Click here to view full article